[go: up one dir, main page]

RU2001116077A - A method for the treatment of cerebral ischemia, as well as the use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischemia - Google Patents

A method for the treatment of cerebral ischemia, as well as the use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischemia

Info

Publication number
RU2001116077A
RU2001116077A RU2001116077/14A RU2001116077A RU2001116077A RU 2001116077 A RU2001116077 A RU 2001116077A RU 2001116077/14 A RU2001116077/14 A RU 2001116077/14A RU 2001116077 A RU2001116077 A RU 2001116077A RU 2001116077 A RU2001116077 A RU 2001116077A
Authority
RU
Russia
Prior art keywords
erythropoietin
use according
treatment
administered
cerebral ischemia
Prior art date
Application number
RU2001116077/14A
Other languages
Russian (ru)
Other versions
RU2242991C2 (en
Inventor
Ханнелоре ЭРЕНРАЙХ
Кристоф ГЛАЙТЕР
Original Assignee
Ханнелоре ЭРЕНРАЙХ
Кристоф ГЛАЙТЕР
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19857609A external-priority patent/DE19857609A1/en
Application filed by Ханнелоре ЭРЕНРАЙХ, Кристоф ГЛАЙТЕР filed Critical Ханнелоре ЭРЕНРАЙХ
Publication of RU2001116077A publication Critical patent/RU2001116077A/en
Application granted granted Critical
Publication of RU2242991C2 publication Critical patent/RU2242991C2/en

Links

Claims (24)

1. Способ лечения церебральных ишемий у млекопитающего, отличающийся тем, что эритропоэтин вводят периферически.1. A method of treating cerebral ischemia in a mammal, characterized in that erythropoietin is administered peripherally. 2. Способ по п.1, отличающийся тем, что осуществляют введение в сосудистую систему.2. The method according to claim 1, characterized in that the introduction of the vascular system. 3. Способ по п.2, отличающийся тем, что осуществляют внутривенное введение.3. The method according to claim 2, characterized in that they carry out intravenous administration. 4. Способ по одному из пп.1-3, отличающийся тем, что эритропоэтин вводят для лечения удара.4. The method according to one of claims 1 to 3, characterized in that erythropoietin is administered to treat stroke. 5. Способ по одному из пп.1-4, отличающийся тем, что эритропоэтин вводят в разовой и/или суточной дозе от 5000 до 100000 ME.5. The method according to one of claims 1 to 4, characterized in that erythropoietin is administered in a single and / or daily dose from 5000 to 100000 ME. 6. Способ по одному из пп.1-5, отличающийся тем, что эритропоэтин вводят в разовой и/или суточной дозе от 35000 ME.6. The method according to one of claims 1 to 5, characterized in that erythropoietin is administered in a single and / or daily dose of 35,000 ME. 7. Способ по одному из пп.1-6, отличающийся тем, что в качестве эритропоэтина вводят нативный или рекомбинантный человеческий или животный эритропоэтин либо их производное.7. The method according to one of claims 1 to 6, characterized in that the native or recombinant human or animal erythropoietin or their derivative is administered as erythropoietin. 8. Способ по одному из пп.1-7, отличающийся тем, что в качестве млекопитающего лечат человека.8. The method according to one of claims 1 to 7, characterized in that the human is treated as a mammal. 9. Применение эритропоэтина для изготовления периферически вводимого лекарства для лечения церебральных ишемий у млекопитающих.9. The use of erythropoietin for the manufacture of peripherally administered drugs for the treatment of cerebral ischemia in mammals. 10. Применение по п.9 для изготовления лекарства, вводимого в сосудистую систему.10. The use according to claim 9 for the manufacture of drugs introduced into the vascular system. 11. Применение по п.10 для изготовления лекарства, вводимого внутривенно.11. The use of claim 10 for the manufacture of a medication administered intravenously. 12. Применение по одному из пп.9-11 для изготовления вводимого периферически лекарства для лечения удара.12. The use according to one of claims 9 to 11 for the manufacture of peripherally administered drugs for the treatment of stroke. 13. Применение по одному из пп.9-12 в разовой и/или суточной дозе от 5000 до 100000 ME.13. The use according to one of claims 9-12 in a single and / or daily dose from 5000 to 100000 ME. 14. Применение по одному из пп.9-13 в разовой и/или суточной дозе от 35000 ME.14. The use according to one of claims 9 to 13 in a single and / or daily dose of 35,000 ME. 15. Применение по одному из пп.9-14, отличающееся тем, что в качестве эритропоэтина используют нативный или рекомбинантный человеческий или животный эритропоэтин либо их производное.15. The use according to one of paragraphs.9-14, characterized in that as erythropoietin use native or recombinant human or animal erythropoietin or their derivative. 16. Применение по одному из пп.9-15, отличающееся тем, что млекопитающее представляет собой человека.16. The use according to one of claims 9 to 15, characterized in that the mammal is a human. 17. Применение эритропоэтина в качестве периферически вводимого средства для лечения церебральных ишемий у млекопитающего.17. The use of erythropoietin as a peripherally administered agent for the treatment of cerebral ischemia in a mammal. 18. Применение по п.17 в качестве средства, вводимого в сосудистую систему.18. The use according to claim 17 as an agent introduced into the vascular system. 19. Применение по п.18 в качестве средства, вводимого внутривенно.19. The use according to p. 18 as a means administered intravenously. 20. Применение по одному из пп.17-19 для лечения удара.20. The use according to one of paragraphs.17-19 for the treatment of stroke. 21. Применение по одному из пп.17-20 в разовой и/или суточной дозе от 5000 до 100000 ME.21. The use according to one of paragraphs.17-20 in a single and / or daily dose from 5000 to 100000 ME. 22. Применение по одному из пп.17-21 в разовой и/или суточной дозе от 35000 ME.22. The use according to one of paragraphs.17-21 in a single and / or daily dose of 35,000 ME. 23. Применение по одному из пп.17-22, отличающееся тем, что в качестве эритропоэтина используют нативный или рекомбинантный человеческий или животный эритропоэтин либо их производное.23. The use according to one of claims 17 to 22, characterized in that the native or recombinant human or animal erythropoietin or their derivative is used as erythropoietin. 24. Применение по одному из пп.17-23, отличающееся тем, что млекопитающее представляет собой человека.24. The use according to one of claims 17 to 23, characterized in that the mammal is a human.
RU2001116077/14A 1998-12-14 1999-12-13 Method for treating cerebral ischemias and application of erythropoietin or its derivatives in treating cerebral ischemias RU2242991C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19857609A DE19857609A1 (en) 1998-12-14 1998-12-14 Use of erythropoietin for the treatment of human cerebral ischemia
DE19857609.9 1998-12-14

Publications (2)

Publication Number Publication Date
RU2001116077A true RU2001116077A (en) 2003-05-20
RU2242991C2 RU2242991C2 (en) 2004-12-27

Family

ID=7891015

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001116077/14A RU2242991C2 (en) 1998-12-14 1999-12-13 Method for treating cerebral ischemias and application of erythropoietin or its derivatives in treating cerebral ischemias

Country Status (26)

Country Link
US (1) US7514072B1 (en)
EP (1) EP1140139B2 (en)
JP (2) JP4750947B2 (en)
KR (1) KR100774827B1 (en)
CN (1) CN1187085C (en)
AT (1) ATE253932T1 (en)
AU (1) AU766216C (en)
BG (1) BG65417B1 (en)
BR (1) BR9916197A (en)
CA (1) CA2353553C (en)
DE (2) DE19857609A1 (en)
DK (1) DK1140139T4 (en)
ES (1) ES2211218T5 (en)
HK (1) HK1042655B (en)
HU (1) HUP0104709A3 (en)
ID (1) ID29107A (en)
IL (2) IL143579A0 (en)
MX (1) MXPA01005971A (en)
NO (1) NO330079B1 (en)
NZ (1) NZ541591A (en)
PL (1) PL202483B1 (en)
PT (1) PT1140139E (en)
RO (1) RO121409B1 (en)
RU (1) RU2242991C2 (en)
WO (1) WO2000035475A2 (en)
ZA (1) ZA200104626B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19857609A1 (en) 1998-12-14 2000-06-15 Hannelore Ehrenreich Use of erythropoietin for the treatment of human cerebral ischemia
US7309687B1 (en) 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
PL352223A1 (en) * 1999-04-13 2003-08-11 Kenneth S Warren Inst Modulation of excitable tissue function by peripherally administered erythropoietin
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7078376B1 (en) 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
DE10043457A1 (en) * 2000-09-04 2002-03-28 Hannelore Ehrenreich Processes for treating schizophrenia and related psychoses, and using erythropoietin or erythropoietin derivatives to treat schizophrenia and related psychoses
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
PA8536201A1 (en) * 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc PROTECTION AND IMPROVEMENT OF CELLS, FABRICS AND ORGANS RESPONDING TO Erythropoietin
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
EP1423509A2 (en) * 2001-08-30 2004-06-02 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use thereof
ATE541921T1 (en) 2001-09-14 2012-02-15 Stem Cell Therapeutics Inc PROLACTIN-INDUCED INCREASE IN NEURONAL STEM CELLS AND ITS THERAPEUTIC APPLICATION
DE10219545A1 (en) * 2002-04-26 2003-11-06 Lang Florian Regulation of apoptosis
JP2005534650A (en) * 2002-06-11 2005-11-17 ザ バーナム インスティテュート Neuroprotective synergism of erythropoietin and insulin-like growth factor
DE10234192B4 (en) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Use of erythropoietin
JP2006521405A (en) * 2003-03-27 2006-09-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Use of erythropoietin in seizure recovery
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
US20070111932A1 (en) * 2003-07-31 2007-05-17 Stem Cell Therapeutics Inc. Method of enhancing and/or inducing neuronal migration using erythropoietin
KR20070008519A (en) 2003-09-29 2007-01-17 워렌 파마슈티칼즈 인코포레이티드 Tissue protective cytokines for the treatment and prevention of sepsis and adhesion formation
CA2543242C (en) * 2003-10-23 2015-04-14 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile freeze-dried aripiprazole formulation and injectable formulation thereof
WO2005077404A1 (en) 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Use of luteinizing hormone (lh) and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
EP1736481A1 (en) 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
US9988427B2 (en) 2005-05-13 2018-06-05 Charite Universitaetsmedizen-Berlin Erythropoietin variants
US20070148100A1 (en) * 2005-09-15 2007-06-28 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
US7534765B2 (en) * 2005-09-27 2009-05-19 Stem Cell Therapeutics Corp. Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactin
EP2004211A4 (en) 2006-03-17 2010-07-07 Stem Cell Therapeutics Corp LH OR HCG AND EPO ASSAY REGIMES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
CA2654154A1 (en) * 2006-06-07 2007-12-13 The University Of Tokushima Treatment of ischemic diseases using erythropoietin
MX2010001311A (en) * 2007-07-31 2010-04-21 Otsuka Pharma Co Ltd Methods for producing aripiprazole suspension and freeze-dried formulation.
RU2446834C2 (en) * 2010-06-15 2012-04-10 Елена Александровна Лебедева Method of treating patients with combined craniocerebral injury
US9956265B2 (en) 2011-04-26 2018-05-01 Ajou University Industry-Academic Cooperation Foundation Composition for aiding surgical procedures for treating ischemic vascular diseases
RU2495688C1 (en) * 2012-03-28 2013-10-20 Государственное бюджетное учреждение здравоохранения Центр организации специализированной медицинской помощи "Челябинский государственный институт лазерной хирургии" Method of treating cerebral ischemia in experiment
US9610444B2 (en) 2013-03-15 2017-04-04 Pacesetter, Inc. Erythropoeitin production by electrical stimulation
KR20190052855A (en) 2017-11-09 2019-05-17 대한제당 주식회사 The composition comprising a PEGylated Erythropoietin for treating ischemic brain disease

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
JPS6197229A (en) 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd Stable erythropoietin preparation
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US5013718A (en) * 1986-11-21 1991-05-07 Amgen, Inc. Method for treating iron overload using EPO
FR2646438B1 (en) 1989-03-20 2007-11-02 Pasteur Institut A METHOD FOR SPECIFIC REPLACEMENT OF A COPY OF A GENE PRESENT IN THE RECEIVER GENOME BY INTEGRATION OF A GENE DIFFERENT FROM THAT OR INTEGRATION
WO1991006667A1 (en) 1989-11-06 1991-05-16 Cell Genesys, Inc. Production of proteins using homologous recombination
HK1000547A1 (en) 1989-12-22 1998-04-03 Merck Serono Sa Endogenous gene expression modification with regulatory element by way of homologous recombination
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
JP3537151B2 (en) * 1991-12-26 2004-06-14 中外製薬株式会社 Prevention and treatment of diseases due to cerebral dysfunction
RU2068268C1 (en) * 1992-03-19 1996-10-27 Учебно-научный центр Медицинского центра при Правительстве РФ Method for preventing cerebrovascular diseases
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5661125A (en) 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
KR960701650A (en) 1993-04-29 1996-03-28 찰스 엠. 브룩 Eythropoietin analog compositions and methods
ZA946122B (en) 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
SE520730C2 (en) 1995-01-20 2003-08-19 Eskil Elmer Treatment of brain ischemia and brain damage with a neuroprotective drug
US6121246A (en) 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US6165783A (en) 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
DE19857609A1 (en) 1998-12-14 2000-06-15 Hannelore Ehrenreich Use of erythropoietin for the treatment of human cerebral ischemia
PL352223A1 (en) 1999-04-13 2003-08-11 Kenneth S Warren Inst Modulation of excitable tissue function by peripherally administered erythropoietin
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs

Similar Documents

Publication Publication Date Title
RU2001116077A (en) A method for the treatment of cerebral ischemia, as well as the use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischemia
RU93054168A (en) DIMER OF THE MOLECULAR OPTION OF ARO-LIPOPROTEIN, METHOD OF ITS PRODUCTION, PHARMACEUTICAL COMPOSITION ON ITS BASIS
ATE209908T1 (en) RADICAL CAPTURER (ßSPIN TRAPSß) FOR THE TREATMENT OF DISEASES ASSOCIATED WITH OXIDATION OF LIPIDS AND PROTEINS
EA200000468A1 (en) THERAPEUTIC COMPOSITION FOR THE ADMINISTRATION OF TOLTERODINE WITH CONTROLLED DELIVERY
HUP0104709A2 (en) Use of erythropoietin or erythropoietin derivatives for the manufacture of a medicament for treatment of cerebral ischaemia
DE60132343D1 (en) FGF-2 FOR THE TREATMENT OF DISEASES OF PERIPHERAL ARTERIES
RU95113492A (en) THERAPEUTIC COMBINATION CONTAINING THE HUMAN INTERFERON, ITS APPLICATION, PHARMACEUTICAL DRUG, PACKAGING AND METHOD OF TREATMENT
RU94022479A (en) Use of antiestrogenic compounds and pharmaceutically acceptable salts and solvents for blood glucose concentration decrease, pharmaceutical preparation
RU95101385A (en) Products containing g-csf and tnf-binding protein
CA2100657A1 (en) Method for treatment of acute and chronic painful arthropathic conditions in human and other mammals
RU97104483A (en) SUITABLE ACID SALT 4- [2-AMINO-6- (CYCLOPROPYLAMINO) -9H-PURIN-9-IL] -2- CYCLOPENTEN-1-METHANOL AS ANTI-VIRUS AGENT
JPH07505608A (en) Treatment of neurological conditions with interleukin-1 inhibitory compounds
RU2000101091A (en) METHOD FOR TREATING DYSTROPHIC DISEASES OF THE RETAIL AND VISUAL NERVE
RU2537560C2 (en) Tetrapeptide and preparation, possessing cerebroprotective and antiamnestic activities (versions)
RU2019180C1 (en) Remedy for treatment of hypodermic fibrosarcoma and method of its preparation
RU95100951A (en) Method of treatment of male sterility
RU2083207C1 (en) Method of treatment of experimental glanders in golden hamsters
RU2063243C1 (en) Agent for radiation disease treatment
SU1666116A1 (en) Method for treatment of trifacial neuralgia
JPS62252729A (en) Promote for recovering hematopoietic function
RU1822775C (en) Method for treatment of trigeminal nerve neuralgia
RU2166960C2 (en) Method for preventing early stage sepsis in children having severe burns
RU2188003C2 (en) Method for treating experimental leprous infection
RU1801001C (en) Method for prophylaxis of acute respiratory diseases in calves
RU1768172C (en) Method for treatment of endomelritis in cows